Pet Brain Tumors

Common among canine and feline brain tumors are canine meningeal tumors, which are astrocytomas and undifferentiated cell sarcomas. Pituitary adenomas are also common in short-headed breeds. Most meningeal tumors occur in dogs over 7 years of age and are located in the cranial cavity. Frequent sites are the convexity of the cerebral hemispheres, the ventral surface of the brain, and the middle cranial fissure area of the brain. Some tumors are located in the space behind the eye in the optic nerve sheath. Brain tumor destroys and compresses brain tissues, obstructs cerebral blood circulation and cerebrospinal fluid flow, and causes cerebral edema. Brain tumours may also form brain hernias, or even brain tissue prolapsing outward from the foramen magnum of the occipital bone.

Primary brain tumours are often slow-growing and clinical symptoms manifest gradually. Severe neurological symptoms appear only when they cause cerebrovascular hemorrhage, infarction, and cachexia. Secondary tumors show clinical symptoms earlier and develop more rapidly. It has been shown that canine brain cancers are very similar to those in children, so perhaps companion dogs with brain cancers can be better saved from now on.

CD200

Tumours secrete a substance called CD200 which acts as a checkpoint inhibitor and blocks the body's natural immune response. We can help you create a canine-specific peptide that overcomes this interaction and allows for a normal immune response. We are actively advancing the combination of immunotherapy with CD200 peptides and vaccines or gene therapy to demonstrate safety and efficacy in dogs with high-grade gliomas.

In addition, we are working to understand the types of immune cells that kill tumor cells and slow disease progression, and whether tumor cells undergo molecular changes as a result of immunotherapy.

YB1 tumor lysing bacterial therapy

Tumors have an area of low oxygen in the center of the tumor, clearly distinguishing it from normal organs. The poor circulation of solid tumors, including some types of brain tumors, results in a high tolerance to various chemotherapeutic drugs, antibody-based drugs, cell-based drugs, etc. Salmonella, as a tumor-loving bacterium, has a strong inhibition of tumor growth and a natural aggregation effect on tumors but damages normal tissues.YB1 is modified by synthetic biology and automatically cleaves in an environment with more than 0.5% oxygen, achieving tumor-specific hoarding and attacking effects.

YB1 can achieve inhibition of tumor growth, rapid enrichment in tumors, and rapid clearance in other normal organs. By targeting the tumor, it can achieve specific survival with excellent safety. And YB1-carrying anti-tumour drugs can achieve high-intensity expression and carrying capacity. It is expected to be applied in the field of pet brain tumors.

Alfa Cytology follows the development and recent breakthroughs in pet brain tumors and tries its best to make its contribution, to targeting brain tumors with CD200 or YB1 we are actively promoting in the field of application. Please feel free to contact us for the latest developments.

Reference

1. Boudreau, C. E., et al. (2021). "Intratumoral Delivery of STING Agonist Results in Clinical Responses in Canine Glioblastoma." Clinical Cancer Research27(20), 5528-5535.